By John McManus, The McManus Group
“There is no terror in the bang, only in the anticipation of it.” – Alfred Hitchcock
As the midterm elections approach, with the trajectory pointing toward increasing likelihood of the Democrats taking control of the House of Representatives and with each Trump tweet on drug pricing, a feeling of foreboding has settled over the pharmaceutical industry.
House Democrats have chosen drug pricing as one of the few substantive issues to campaign on, believing that their energized but fractured based needs little other motivation to recapture a key branch of government. In the August recess packet Democrat Leader Nancy Pelosi (D-CA) sent home with her members, point one said: “Our closing argument: For the People” is lowering your health costs and prescription drug prices.